The participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except =< grade  alopecia, neuropathy, and other non-clinically significant adverse events (AEs)
Prior treatment-related adverse events (AEs) must be =< grade  (Common Terminology Criteria for Adverse Events [CTCAE] v.), except alopecia, at time of initiating study drug
The subjects who have not recovered to baseline or CTCAE ? Grade  from related toxicity to all prior therapies will be excluded. Patients with Non-serious adverse events such as alopecia, fatigue, weakness, loss of appetite and nausea that are non-significant will not be excluded.
The participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
Recovery from all adverse events (AEs) of previous anti-cancer therapies, including surgery, chemotherapy and radiotherapy, to baseline or to Common Terminology Criteria for Adverse Events (CTCAE) grade =< , except for alopecia
The subject has not recovered to baseline, Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies for RCC or to a level permitted under other sections of the eligibility criteria except alopecia and other non-clinically significant adverse events (AEs)
Patients who have received palliative radiotherapy within  weeks of study entry and have not recovered to grade  or baseline from associated toxicities. Note: Patients may receive palliative radiation once enrolled on study. The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies, including surgery, except alopecia and other non-clinically significant adverse events (AEs).
Subject has not fully recovered to baseline or National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) ? Grade  from toxicity due to all prior therapies, except alopecia and other non-clinically significant AEs.
Prohibited anti-NSCLC therapies and not having recovered from related AEs to Common Terminology Criteria for Adverse Events (CTCAE) Grade ?
The subject has not recovered to baseline or CTCAE =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs.
The subjects who have not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from related toxicity to all prior therapies will be excluded; patients with non-serious adverse events such as alopecia, fatigue, weakness, loss of appetite and nausea that are non-significant will not be excluded
The subject has not recovered to baseline or Common Terminology Criteria For Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
mCRPC EXPANSION COHORT: The patient has not recovered to baseline or CTCAE =< grade  from toxicity due to all prior therapies, including surgery, except alopecia and other non-clinically significant adverse events (AEs)
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has not recovered to baseline or CTCAE =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan; the subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< Grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs) (e.g. albumin)
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from related toxicity to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicities related to prior treatment, except alopecia, lymphopenia, other non-clinically significant adverse events (AEs)
Common Terminology Criteria for Adverse Events (CTCAE) recovered to baseline or CTCAE =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
Not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia, oxaliplatin-related neuropathy, asymptomatic electrolyte abnormalities =< grade , and other non-clinically significant adverse events
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
Patients must have recovered from effects of recent surgery, radiotherapy, chemotherapy or biologic/targeted therapy to baseline or Common Terminology Criteria for Adverse Events (CTCAE) less than or equal to grade  (excluding alopecia or other non-clinically significant adverse events [AE's])
Recovery from effects of recent treatment to baseline or CTCAE =< grade  toxicity from all prior therapies except alopecia and other non-clinically significant adverse events (AEs), unless the principal investigator (PI) determination is that the electrolyte imbalance is a result of the disease process
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies, including surgery, except alopecia and other non-clinically significant adverse events (AEs)
The participant has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs) defined as lab elevation with no associated symptoms or sequelae
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
The subject has not recovered to baseline or Common Terminology Criteria for Adverse Events (CTCAE) =< grade  from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)
